Impact of CT-apelin and NT-proBNP on identifying non-responders to cardiac resynchronization therapy

References

• Anand IS, Fisher LD, Chiang YT, et al. (2003). Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107:1278–83.
   PubMed Web of Science ®Google Scholar
• Ashley EA, Powers J, Chen M, et al. (2005). The endogenous peptide apelin potently improves cardiac contractility and reduces cardiac loading in vivo. Cardiovasc Res 65:73–82.
   PubMed Web of Science ®Google Scholar
• Barnes GD, Alam S, Carter G, et al. (2013). Sustained cardiovascular actions of APJ agonism during renin-angiotensin system activation and in patients with heart failure. Circ Heart Fail 6:482–91.
   PubMed Web of Science ®Google Scholar
• Bellenger NG, Burgess MI, Ray SG, et al. (2000). Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance; are they interchangeable? Eur Heart J 21:1387–96.
   PubMed Web of Science ®Google Scholar
• Berger R, Shankar A, Fruhwald F, et al. (2009). Relationships between cardiac resynchronization therapy and N-terminal pro-brain natriuretic peptide in patients with heart failure and markers of cardiac dyssynchrony: an analysis from the Cardiac Resynchronization in Heart Failure (CARE-HF) study. Eur Heart J 30:2109–16.
   PubMed Web of Science ®Google Scholar
• Berry MF, Pirolli TJ, Jayasankar V, et al. (2004). Apelin has in vivo inotropic effects on normal and failing hearts. Circulation 110:II187–93.
   PubMed Web of Science ®Google Scholar
• Blondheim DS, Beeri R, Feinberg MS, et al. (2010). Reliability of visual assessment of global and segmental left ventricular function: a multicenter study by the Israeli Echocardiography Research Group. J Am Soc Echocardiogr 23:258–64.
   PubMed Web of Science ®Google Scholar
• Brenyo A, Barsheshet A, Rao M, et al. (2013). Brain natriuretic peptide and cardiac resynchronization therapy in patients with mildly symptomatic heart failure. Circ Heart Fail 6:998–1004.
   PubMed Web of Science ®Google Scholar
• Brignole M, Auricchio A, Baron-Esquivias G, et al. (2013). 2013 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy: the Task Force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Eur Heart J 34:2281–329.
   PubMed Web of Science ®Google Scholar
• Bristow MR, Saxon LA, Boehmer J, et al. (2004). Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 350:2140–50.
   PubMed Web of Science ®Google Scholar
• Chan PS, Khumri T, Chung ES, et al. (2010). Echocardiographic dyssynchrony and health status outcomes from cardiac resynchronization therapy: insights from the PROSPECT trial. JACC Cardiovasc Imaging 3:451–60.
   PubMed Web of Science ®Google Scholar
• Chen MM, Ashley EA, Deng DX, et al. (2003). Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108:1432–9.
   PubMed Web of Science ®Google Scholar
• Chong KS, Gardner RS, Morton JJ, et al. (2006). Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 8:355–60.
   PubMed Web of Science ®Google Scholar
• Cleland JG, Daubert JC, Erdmann E, et al. (2005). The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 352:1539–49.
   PubMed Web of Science ®Google Scholar
• Farkasfalvi K, Stagg MA, Coppen SR, et al. (2007). Direct effects of apelin on cardiomyocyte contractility and electrophysiology. Biochem Biophys Res Commun 357:889–95.
   PubMed Web of Science ®Google Scholar
• Foldes G, Horkay F, Szokodi I, et al. (2003). Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 308:480–5.
   PubMed Web of Science ®Google Scholar
• Fornwalt BK, Sprague WW, BeDell P, et al. (2010). Agreement is poor among current criteria used to define response to cardiac resynchronization therapy. Circulation 121:1985–91.
   PubMed Web of Science ®Google Scholar
• Francia P, Salvati A, Balla C, et al. (2007). Cardiac resynchronization therapy increases plasma levels of the endogenous inotrope apelin. Eur J Heart Fail 9:306–9.
   PubMed Web of Science ®Google Scholar
• Fruhwald FM, Fahrleitner-Pammer A, Berger R, et al. (2007). Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 28:1592–7.
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Hall WJ, Beck CA, et al. (2011). Reduction of the risk of recurring heart failure events with cardiac resynchronization therapy: MADIT-CRT (Multicenter Automatic Defibrillator Implantation Trial With Cardiac Resynchronization Therapy). J Am Coll Cardiol 58:729–37.
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Kutyifa V, Klein HU, et al. (2014). Survival with cardiac-resynchronization therapy in mild heart failure. N Engl J Med 370:1694–701.
   PubMed Web of Science ®Google Scholar
• Goldenberg I, Moss AJ, Hall WJ, et al. (2011). Predictors of response to cardiac resynchronization therapy in the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 124:1527–36.
   PubMed Web of Science ®Google Scholar
• Hartmann F, Packer M, Coats AJ, et al. (2004). Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110:1780–6.
   PubMed Web of Science ®Google Scholar
• Hsu JC, Solomon SD, Bourgoun M, et al. (2012). Predictors of super-response to cardiac resynchronization therapy and associated improvement in clinical outcome: the MADIT-CRT (multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy) study. J Am Coll Cardiol 59:2366–73.
   PubMed Web of Science ®Google Scholar
• Japp AG, Cruden NL, Barnes G, et al. (2010). Acute cardiovascular effects of apelin in humans: potential role in patients with chronic heart failure. Circulation 121:1818–27.
   PubMed Web of Science ®Google Scholar
• Japp AG, Newby DE. (2008). The apelin-APJ system in heart failure: pathophysiologic relevance and therapeutic potential. Biochem Pharmacol 75:1882–92.
   PubMed Web of Science ®Google Scholar
• Kuba K, Zhang L, Imai Y, et al. (2007). Impaired heart contractility in Apelin gene-deficient mice associated with aging and pressure overload. Circ Res 101:e32–42.
   PubMed Web of Science ®Google Scholar
• Maisel A. (2011). Biomonitoring and biomarker-guided therapy: the next step in heart failure and biomarker research. J Am Coll Cardiol 58:1890–2.
   PubMed Web of Science ®Google Scholar
• Maisel AS, Choudhary R. (2012). Biomarkers in acute heart failure – state of the art. Nat Rev Cardiol 9:478–90.
   PubMed Web of Science ®Google Scholar
• Masson S, Latini R, Anand IS, et al. (2008). Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol 52:997–1003.
   PubMed Web of Science ®Google Scholar
• Miettinen KH, Magga J, Vuolteenaho O, et al. (2007). Utility of plasma apelin and other indices of cardiac dysfunction in the clinical assessment of patients with dilated cardiomyopathy. Regul Pept 140:178–84.
   PubMedGoogle Scholar
• Moss AJ, Hall WJ, Cannom DS, et al. (2009). Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 361:1329–38.
   PubMed Web of Science ®Google Scholar
• O'Carroll AM, Lolait SJ, Harris LE, Pope GR. (2013). The apelin receptor APJ: journey from an orphan to a multifaceted regulator of homeostasis. J Endocrinol 219:R13–35.
   PubMed Web of Science ®Google Scholar
• Perjes A, Skoumal R, Tenhunen O, et al. (2014). Apelin increases cardiac contractility via protein kinase Cɛ- and extracellular signal-regulated kinase-dependent mechanisms. PLoS One 9:e93473.
   Google Scholar
• Rickard J, Cheng A, Spragg D, et al. (2014). Durability of the survival effect of cardiac resynchronization therapy by level of left ventricular functional improvement: fate of “nonresponders”. Heart Rhythm 11:412–16.
   PubMed Web of Science ®Google Scholar
• Shanks M, Delgado V, Ng AC, et al. (2011). Clinical and echocardiographic predictors of nonresponse to cardiac resynchronization therapy. Am Heart J 161:552–7.
   PubMed Web of Science ®Google Scholar
• Siddiquee K, Hampton J, Khan S, et al. (2011). Apelin protects against angiotensin II-induced cardiovascular fibrosis and decreases plasminogen activator inhibitor type-1 production. J Hypertens 29:724–31.
   PubMed Web of Science ®Google Scholar
• Szokodi I, Tavi P, Foldes G, et al. (2002). Apelin, the novel endogenous ligand of the orphan receptor APJ, regulates cardiac contractility. Circ Res 91:434–40.
   PubMed Web of Science ®Google Scholar
• Tatemoto K, Takayama K, Zou MX, et al. (2001). The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 99:87–92.
   PubMed Web of Science ®Google Scholar
• Wang W, McKinnie SM, Patel VB, et al. (2013). Loss of Apelin exacerbates myocardial infarction adverse remodeling and ischemia-reperfusion injury: therapeutic potential of synthetic Apelin analogs. J Am Heart Assoc 2:e000249.
   PubMed Web of Science ®Google Scholar
• Zareba W, Klein H, Cygankiewicz I, et al. (2011). Effectiveness of cardiac resynchronization therapy by QRS Morphology in the Multicenter Automatic Defibrillator Implantation Trial-Cardiac Resynchronization Therapy (MADIT-CRT). Circulation 123:1061–72.
   PubMed Web of Science ®Google Scholar